Globe Newswire01.26.22
RenovaCare Inc. has expanded its proprietary cell isolation and spray technology portfolio with a new SkinGun patent.
The RenovaCare SkinGun provides a non-invasive gentle cell spray to facilitate burn wound healing. Its expanding patent portfolio creates additional commercial opportunities in cell therapies, biologics, drug delivery, and other areas, allowing for strategic business alliances with potential partner companies. RenovaCare was granted full Investigational Device Exemption by the U.S. Food and Drug Administration in May 2021, paving the way for a clinical trial to evaluate the safety and feasibility of the SkinGun and CellMist System. The CELLMIST 1 clinical trial utilizes the RenovaCare SkinGun and CellMist System to topically administer autologous skin cells onto deep second-degree thermal burn wounds in adults to facilitate healing. The CELLMIST 1 clinical trial is ongoing and screening U.S. patients for enrollment.
“The RenovaCare patent portfolio is comprised of eight patent families spanning the United States, Europe, Australia, and Asia. Having already successfully defended its IP portfolio, the company has issued patents extending to 2037. Issued patents include cell isolation techniques for skin and other tissues and a cell spray gun that is highly effective in spraying various biologically compatible liquids and cell suspensions of all types. RenovaCare owns all technology developed and under development and has not in-licensed any technology, which increases the value of our IP,” stated Dr. Rodney Sparks, vice president of Intellectual Property at RenovaCare.
The latest patent follows numerous technological breakthroughs at RenovaCare and expansion of the company’s intellectual property portfolio, with additional patents granted in the United States, Australia, Canada, and select European and Asian jurisdictions. RenovaCare's most recent patent demonstrates the firm’s commitment to developing new products and expanding its proprietary cell isolation and spray technology platforms to now include biologics and drug delivery.
“RenovaCare has adopted a global IP strategy focused on investing in technology and broadening our commercial opportunities domestically and abroad,” stated Dr. Kaiyo Nedd, RenovaCare CEO and president. “A stronger patent portfolio better secures our technology from third-party appropriation and infringement while enhancing the value of our corporate assets.”
RenovaCare Inc. is developing new autologous stem cell therapies for the regeneration of human organs and tissues. The company’s initial product under development targets the skin. Its flagship technology, the CellMist System, renders single-cell suspensions of tissue-specific pluripotent cells from donor tissues through sequential protease digestions. The RenovaCare CellMist System facilitates rapid healing of wounds or other afflicted tissues when applied topically as a gentle cell mist using the patented RenovaCare SkinGun. The SkinGun is used to spray a liquid suspension of a patient’s stem cells—the CellMist Solution—on to wounds.
The RenovaCare SkinGun provides a non-invasive gentle cell spray to facilitate burn wound healing. Its expanding patent portfolio creates additional commercial opportunities in cell therapies, biologics, drug delivery, and other areas, allowing for strategic business alliances with potential partner companies. RenovaCare was granted full Investigational Device Exemption by the U.S. Food and Drug Administration in May 2021, paving the way for a clinical trial to evaluate the safety and feasibility of the SkinGun and CellMist System. The CELLMIST 1 clinical trial utilizes the RenovaCare SkinGun and CellMist System to topically administer autologous skin cells onto deep second-degree thermal burn wounds in adults to facilitate healing. The CELLMIST 1 clinical trial is ongoing and screening U.S. patients for enrollment.
“The RenovaCare patent portfolio is comprised of eight patent families spanning the United States, Europe, Australia, and Asia. Having already successfully defended its IP portfolio, the company has issued patents extending to 2037. Issued patents include cell isolation techniques for skin and other tissues and a cell spray gun that is highly effective in spraying various biologically compatible liquids and cell suspensions of all types. RenovaCare owns all technology developed and under development and has not in-licensed any technology, which increases the value of our IP,” stated Dr. Rodney Sparks, vice president of Intellectual Property at RenovaCare.
The latest patent follows numerous technological breakthroughs at RenovaCare and expansion of the company’s intellectual property portfolio, with additional patents granted in the United States, Australia, Canada, and select European and Asian jurisdictions. RenovaCare's most recent patent demonstrates the firm’s commitment to developing new products and expanding its proprietary cell isolation and spray technology platforms to now include biologics and drug delivery.
“RenovaCare has adopted a global IP strategy focused on investing in technology and broadening our commercial opportunities domestically and abroad,” stated Dr. Kaiyo Nedd, RenovaCare CEO and president. “A stronger patent portfolio better secures our technology from third-party appropriation and infringement while enhancing the value of our corporate assets.”
RenovaCare Inc. is developing new autologous stem cell therapies for the regeneration of human organs and tissues. The company’s initial product under development targets the skin. Its flagship technology, the CellMist System, renders single-cell suspensions of tissue-specific pluripotent cells from donor tissues through sequential protease digestions. The RenovaCare CellMist System facilitates rapid healing of wounds or other afflicted tissues when applied topically as a gentle cell mist using the patented RenovaCare SkinGun. The SkinGun is used to spray a liquid suspension of a patient’s stem cells—the CellMist Solution—on to wounds.